Utilizing affinity chromatography, a C3-specific binding protein was isolated from "2I surface-labeled human platelets. Analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis demonstrated two bands with mean Mr of 64,000 and 53,000, characteristic variability in the relative density of the two bands in a given individual, and the presence of N-linked complex oligosaccharides as well as sialic acid residues not associated with N-linked sugars. These characteristics are similar to those of a human leukocyte iC3-and C3b-binding glycoprotein, termed gp45-70. Further analysis showed that leukocyte gp45-70 and the platelet C3-binding glycoprotein have identical Mr and other similar structural features. Functional characterization of solubilized platelet preparations indicated that gp45-70 has cofactor activity. This membrane glycoprotein is structurally and antigenically distinct from decay accelerating factor (DAF), a complement regulatory protein previously identified on human platelet membranes. DAF and gp45-70 have complementary activity profiles inasmuch as DAF can prevent assembly of and dissociate the C3 convertases but has no cofactor activity, whereas gp45-70 has cofactor activity but no decay accelerating activity. We suggest that these two proteins function conjointly to prevent autologous complement activation.
Introduction
A number of membrane proteins capable of binding the third component of complement (C3) have been identified (1) (2) (3) . On human peripheral blood cells, the C3b/C4b receptor (CR1) was the first to be described biochemically (4, 5) and is a single-chain integral membrane glycoprotein with an Mr of -200,000. This molecule has been identified on erythrocytes, granulocytes, monocytes, macrophages, B lymphocytes, and a subpopulation of T cells and glomerular podocytes (6) . It exhibits a number of interesting cell-specific structural features and a polymorphism in which four autosomal codominantly inherited alleles have Mr between 160,000 and 250,000 (7-1 1). CR2, the C3d or C3dg receptor, is a single-chain integral membrane glycoprotein with a Mr of 140,000 (12) (13) (14) . This molecule is found on B lymphocytes (1) (2) (3) and has also recently been shown to be the "receptor" for the Epstein-Barr virus (15, 16) . CR3, the receptor for C3bi, (17) (18) (19) (20) (21) (22) ).
An additional C3b/C4b-binding membrane protein, termed gp45-70, has been identified (23, 24) . It binds iC3 and C3b but not C3d and is widely distributed on human peripheral blood mononuclear cells. On most cells this glycoprotein is a doublet with a predominant upper band and has an Mr between 45,000 and 70,000. Gp45-70 has a similar Mr to C3b-binding proteins previously described on rabbit macrophages (25, 26) and, more recently, on murine cells (27) . The human and murine molecules do not appear to mediate rosette formation and the physiologic function of gp45-70 is unknown.
Human platelets do not possess CR 1, CR2, or CR3 but have been shown to possess decay accelerating factor (DAF)' (28, 29) . This -70,000-Mr regulatory membrane protein isalso found on erythrocytes and leukocytes and facilitates the decay of both the classical and alternative pathway C3 convertases (28) (29) (30) . However, DAF does not bind to C3b or C4b affinity columns and, in contrast to other human peripheral blood cells, no C3b-binding molecules have been identified on platelets (1) (2) (3) . In this report, we have identified a C3-binding membrane protein of human platelets and provided evidence that it has regulatory activity for the complement system.
Methods
Purification ofplatelets and leukocytes. Platelets and leukocytes were purified from 150 ml of blood collected in 3.5 ml of 0.25 M Na2EDTA from normal individuals on the day of use. Platelets were purified as described (31) with minor modifications. All procedures were performed at room temperature using plastic ware only. After centrifugation of whole blood at 1,000 g for 3 min at 25°C, platelet-rich plasma was removed. Platelets were then sedimented by centrifugation at 2,000 g for 10 min at 25°C. The pellet was then resuspended with wash buffer (0.113 M NaCl, 4.3 mM K2HPO4, 4.3 mM Na2HPO4, 24.5 mM NaH2PO4, 5.5 mM dextrose, pH 6.5) and centrifuged at 120 g for 10 min to sediment contaminating erythrocytes and leukocytes. This centrifugation step was then repeated twice more. Platelets were then again sedimented and washed twice with wash buffer. Approximately 4 X 109 platelets were obtained from 150 ml of whole blood. Microscopic examination of the purified platelet preparations revealed less than one leukocyte per 104 platelets. Mononuclear leukocytes were purified from whole blood by dextran sedimentation followed by bouyant density centrifugation employing Ficoll-Hypaque (24, 32 Affinity chromatography. Affinity chromatography was peformed as previously described (8, 24, 34) . Affinity columns were prepared by two methods: (a) iC3, BSA, or human IgG was coupled to cyanogen bromideactivated Sepharose (Sepharose 6B, Sigma Chemical Co.) as previously described (7, 8) or (b) C3b-and C3d-thiol-Sepharose were prepared by methods also described previously (13, 24) .
Solubilized preparations were first preincubated with IgG-Sepharose for I h with constant mixing at room temperature (0.2 ml of packed beads per 1 ml of solubilized preparation). The supernatant was then removed, diluted threefold to 0.05 M NaCi with distilled water, and incubated with the protein-coupled Sepharose for 1 h at room temperature with constant mixing. The affinity column was then washed with 0.05 M PBS, 1% NP-40 and eluted with 400 mM NaCl, 1% NP-40. After dialysis against distilled H20, Iyophilization and acetone precipitation, samples were prepared for sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) or enzyme treatments.
Evaluation of the efficiency of this methodology showed that >80% of the leukocyte or platelet-binding proteins specific for a given column were removed by the initial incubation. A second or third incubation removed >95% of specific binding proteins. The pattern on SDS-PAGE of the eluates from these additional incubations was identical to that of the first eluate. Also, C3b-affinity columns were eluted first with high salt and then with 6 M guanidine. The eluates were compared by SDS-PAGE. No new specific bands were eluted by 6 M guanidine. Further, >70% of the counts in the C3b-specific bands were eluted by high salt.
Immunoprecipitation. Immunoprecipitation was performed as previously described (8, 34) . Antibodies utilized were monoclonal anti-CRI antibody 57F (gift of V. Nussenzweig, Department of Pathology, New York University, New York City) and polyclonal antibodies raised in rabbits to H, C4-binding protein (C4bp), DAF, and CR1 (8, 35) . For all immunoprecipitations, parallel conditions were run with MOPC-21 (as a nonspecific monoclonal antibody of the same isotype as 57F) and rabbit serum or rabbit IgG (as a control for the polyclonal antisera). The antibody to DAF was a generous gift of Dr. Michael Pangburn (Department of Biochemistry, University of Texas Health Science Center, Tyler) and was an IgG fraction.
Briefly, solubilized preparations were first precleared of nonspecific proteins with Staphylococcus aureus (Cowan I strain) and then incubated with either specific or nonspecific polyclonal or monoclonal antibody for 1 h at 4°C. For the monoclonal immunoprecipitation, a rabbit antimouse second antibody was then added and incubation continued for I h at 4°C. This preparation was then incubated in Staph Cowan for 15 min and, after several washings with PBS and 1% NP40, bound proteins were eluted.
Enzyme treatment. Enzyme treatments were performed as described (34, 36) with minor modifications. Radioiodinated material was resuspended in 0.10 ml of the appropriate buffer for treatment with neuraminidase (50 mM sodium acetate, I mM CaC12, 0.2% NP40, pH 5.5) or endoglycosidase (Endo) F (100 mM NaH2PO4, 50 mM EDTA, 1% NP40, 0.1% SDS, 1% 0-mercaptoethanol, pH 6.1). The preparation was heated at 80°C for 10 min and then allowed to cool to room temperature. For most experiments Endo F or neuraminidase was then added in a 0.02-ml aliquot containing 60 mU and a second 60-mU was added at 3 h. After a total incubation period of6 h at 370C, treatment was terminated by precipitating the samples with I ml of acetone at -200C for 5 h. Precipitated samples were then recovered by centrifugation and prepared for additional enzyme treatments or SDS-PAGE.
SDS-PAGE and autoradiography. SDS-PAGE was performed as previously described (7, 8, 37, 38) , using a 7.5% or 6-18% polyacrylamide gel. All samples were loaded onto a 3% stacking gel. On reduced gels, samples were treated with 5% (3-mercaptoethanol and heated at 80C for 10 min. Autoradiographic methodology has been described (8 (35) .
For these functional studies, purified platelets solubilized in the presence of protease inhibitors (2 mM phenylmethylsulfonyl fluoride, 3 mM EDTA, 1 uM pepstatin, 20 mM iodoacetamide) were first precleared. Anti-human C4bp and anti-human CR1 rabbit polyclonal antibodies were prepared as described (35 For assessment ofcofactor activity ofiC3-or BSA-Sepharose eluates, samples were first dialyzed against dH2O and then against PBS, pH 7.4. The assay was then performed as described above. Alpha chain cleavage was determined by densitometric scanning of the a2 and a2 fragments.
Results
Identification of a C3-binding platelet membrane protein. Incubation of labeled solubilized platelet preparation with IgG-, BSA-, or iC3-Sepharose beads, elution of these columns, and analysis of the eluates by SDS-PAGE followed by autoradiography revealed an iC3-binding protein with an Mr between 50,000 and 68,000 ( Fig. 1 ). This molecule specifically binds to iC3 (track 3) and is a doublet consisting of two relatively broad bands. The mean Mr ofthe "upper" and "lower" bands is 64,000 and 53,000, respectively. Molecules with M, of42,000 and 53,000 are prominent in the IgG lane; this Mr is in the range expected for the Fcy receptor (39) (40) (41) . Two prominent bands with an Mr of 132,000 and 90,000 bound to all three columns. These bands also appear in autoradiographs of immunoprecipitations of solubilized platelet preparations (see below) and are the most heavily labeled bands of solubilized material applied directly to gels. Furthermore, while the bands at 64,000 and 53,000 Mr are specifically inhibited by fluid phase iC3 (see below), the 132,000-and 90,000-Mr bands are unaltered.
Consistent with previously reported functional studies (1, 2), CR1 with an Mr of -200,000 or CR2 with an Mr of 140,000
was not found in the iC3 eluate (also see Fig. 7 ). This lack of CR1 was further confirmed by an immunoprecipitation employing a polyclonal anti-CR1 antibody (not shown). Finally, no band with an Mr of 70,000-75,000 corresponding to that reported for DAF is present on the autoradiograph in Fig. 1 densitometric scanning. This ratio (Fig. 1, track 3 and Fig. 3 , track 2) was observed in six of the eight donors studied. The other two patterns, observed in one donor each, are an approximately "equal doublet" in which at least 30% of counts are in each band (Fig. 3, track 3) , and one in which >70% ofthe counts are in the lower Mr band (Fig. 3, track 4) . Multiple (more than three) purifications ofone individual of each type over a 12-mo period have shown that the pattern is stable.
Reduction of plt-C3BP with ,8-mercaptoethanol results in a 6,000-Mr increase for both bands, suggesting the presence of intrachain disulfide linkages. Upon reduction, the lower band is more sharply focused and thus appears to be more prominent (Fig. 3 b, two additional gels comparing reducing and nonreducing patterns are shown in Fig. 7 ). Also, with reduction a third band slightly below the lower band, although faint, is usually observed.
Specificity ofplt-C3BPfor C3 and itsfragments. To further demonstrate that plt-C3BP isolated by iC3-Sepharose affinity chromatography is a C3-specific binding protein, fluid-phase inhibition and binding specificity studies were performed. In fluid-phase inhibition studies, proteins were preincubated or simultaneously incubated with the solubilized platelet preparation and iC3-Sepharose. Fluid-phase iC3 inhibited binding of plt-C3BP to iC3-Sepharose (Fig. 4) but had no effect on the two proteins of 90,000 and 132,000 Mr (not shown). was greater than anticipated based on the quantity ofiC3 bound to the Sepharose (assuming that there is equal affinity of the binding protein for fluid phase and Sepharose-bound iC3). This may be due to a number of factors, including the possibility that a fraction of the iC3 coupled to the Sepharose is oriented such that the binding site is not optimally exposed.
In a second type of study binding specificity of plt-C3BP for C3 and its derivatives was evaluated. Radiolabeled platelet membranes were evaluated by affinity chromatography with iC3-Sepharose and C3b-and C3d-thiol-Sepharose (Fig. 5) . Multiple experiments indicated that plt-C3BP bound to iC3-Sepharose and to C3b-thiol-Sepharose (Fig. 5 a) , but binds minimally to C3d-thiol-Sepharose (Fig. 5 b) . Taken together, these results indicate that the binding region for plt-C3BP resides in the C3c portion of C3 (24) .
Effect ofglycosidase treatments on the Mr ofplt-C3BP. One explanation for the Mr heterogeneity observed for plt-C3BP is a variation in oligosaccharide structure. To address this possibility, labeled plt-C3BP was purified by affinity chromatography and subjected to treatment with neuraminidase, an enzyme that cleaves sialic acid residues, and Endo F, an enzyme that removes N-linked oligosaccharides. The effects of these enzymatic treatments were assessed by SDS-PAGE and autoradiography using an individual with a predominant upper band pattern (Fig. 6) .
As seen in this and other similar experiments, treatment with Endo F results in the upper and lower Mr bands of plt-C3BP each being resolved into two bands (track 2). There is a 3,000-4,000 reduction in M, ofpart ofeach band ofthe molecule, suggesting the presence ofat least one and possibly two N-linked oligosaccharide unit(s). However, the Mr difference between the upper and lower bands is not reduced. Incomplete digestion (42, 43) or the presence of two separate classes of molecules could explain this result. (44) .
A comparison ofplt-C3BP andgp45-70 ofhuman peripheral blood leukocytes and cell lines. The two band pattern exhibited by plt-C3BP on SDS-PAGE, its ligand specificity, and the effect of glycosidase digestions on the Mr of this molecule suggested that this glycoprotein shares many characteristics with a recently described C3-binding glycoprotein of human peripheral blood leukocytes and monocyte-derived cell lines, termed gp45-70 (24) . To further compare these proteins, human mononuclear leukocytes (Ficoll-Hypaque interface) and platelets were purified from the same donor and surface radioiodinated and solubilized. C3-binding proteins were then isolated by affinity chromatography and analyzed. Autoradiographs demonstrate that plt-C3BP and gp45-70 align by SDS-PAGE (Fig. 7) . In addition, the relative band density of the two major bands of this protein is similar for both cell types for a given individual. This is most clearly demonstrated in tracks 3 and 4 (donor B) in which an individual with a predominant lower band pattern was studied.
No band that aligns with CR1 is seen but a faint band migrating at the Mr of approximately 140,000 is present (Fig. 7 a) .
The possibility that this band represents CR2 (marked on leukocyte lanes of Fig. 7 ) was discounted as it also binds to BSASepharose columns and does not align with CR2 upon reduction (Fig. 7 b) . These data are consistent with prior functional and structural studies indicating that human platelets do not possess CR1 or CR2 (1-3) . The absence ofthese receptors also indicates that there is no significant contamination of the platelet preparations with leukocytes, confirming our microscopic studies.
Cofactor activity ofplt-C3BP. In preliminary experiments, J. Turner (45) showed that eluates of an iC3-Sepharose column to which solubilized preparations ofU937 had been applied possessed cofactor activity for the I-mediated cleavage of C3. Our laboratory has recently found that this cofactor activity is largely attributable to gp45-70 and that purified gp45-70 from U937 and HSB-2 has cofactor activity (46). We therefore determined if the platelet preparations contained such an activity (Fig. 8) .
Purified human platelets solubilized in the presence of protease inhibitors were precleared of known cofactors, H, C4bp, and CR1, and then incubated with '25I-labeled iC3 and I. As controls, 1251-iC3 was incubated with H, H + I, or I alone. Analysis of iC3 cleavage fragments by SDS-PAGE and autoradiography (Fig. 8) shows that solubilized platelet preparations contain I-dependent cofactor activity (lanes 3-7) . The a-chain of iC3 was cleaved into a1 (Mr 75,000) and a2 (Mr 46,000), which was further cleaved to a'2 (Mr 43,000). These cleavage products are of identical Mr to those generated by I + H (Fig. 8, lane 8) . In addition, this cleavage exhibited dose-dependency since increasing concentrations of platelet preparation resulted in greater achain cleavage.
To evaluate whether this activity binds to iC3, platelet preparations were incubated with IgG-Sepharose and then with either BSA-or iC3-Sepharose. Eluates of these columns were then In the course of these studies, we noted the similarities between plt-C3BP and gp45-70 of human leukocytes (24) . The Mr ofthe two bands ofthe molecule ofboth platelets and leukocytes were identical on SDS-PAGE. Furthermore, individuals with a predominantly upper or lower band pattern for their leukocyte gp45-70 display the same pattern on their platelets. In addition, results of glycosidase digestions of gp45-70 of U937 and HSB-2 are identical to those obtained here for platelets (44) (45) (46) . Analysis by two-dimensional gels also shows plt-C3BP (unpublished data) and gp45-70 (44) to both have very acidic isoelectric points (43, 44) , compatible with the large amount of sialic acid on the molecule. Both molecules also bind to the C3c portion of C3 (24) . These similarities of structure and binding specificity indicate that plt-C3BP and gp45-70 of human mononuclear leukocytes are identical.
For all donors evaluated the two bands that comprise this C3 binding protein have identical Mr. In contrast, the relative amount ofthe upper and lower band varied widely among donors but was reproducible in a given individual. A partial explanation for the Mr difference between the two bands was provided by glycosidase digestions. Platelet gp45-70 possesses complex Nlinked oligosaccharides and evidence was obtained for sialic acid residues that were not associated with N-linked sugars (probably O-linked oligosaccharides). An increased number of these sialic acid residues was found on the higher M, form of this molecule.
In progress are studies ofthe inheritance pattern of this molecule and further comparative structural analyses of the two bands. Such experiments should permit us to determine ifthis unusual two band pattern represents allelic variants or two distinct glycoprotein species.
In addition to the initial identification of this glycoprotein on platelets and its structural and functional similarity to gp45- 70, another important finding was that platelet gp45-70 has cofactor activity. The possibility that this cleavage was caused by other known cofactors such as H, C4bp and CR1 was assessed and excluded. In addition, the activity observed was not likely to be due to nonspecific proteases as appropriate inhibitors were present and the activity was I-dependent. This platelet-associated cofactor activity was assigned to a C3-specific binding molecule; that is, the activity in solubilized platelet preparations specifically bound to and eluted from an iC3-Sepharose column. Affinity chromatography of solubilized surface labeled platelets leads to the isolation of platelet gp45-70 as the only C3-specific binding protein on platelet membranes. It is likely, therefore, that platelet gp45-70 is responsible for the cofactor activity. Finally, gp45-70 has recently been purified from leukocytes and shown to have cofactor activity (46, 47) .
Though human platelets do not possess complement receptors (CR1. or CR2), they have previously been shown to possess another protein which regulates complement activation, decay wcdcIrating factor or DAF (28, 29) . DAF dissociates (30) and prevents assembly of the C3 convertases (48); however, it has no cofactir activity (30) . DAF on human erythrocytes has several other reties ofnote including the ability to insert into erythrocyte membranes; in addition, it possesses decay accelerating activity only for C3b or C4b inserted into the same membrane upon which the IDAF itself is located (so called intrinsic decay acceleratifng activity) (48,. 49) .
